HCWB logo

HCW Biologics Inc.

HCWB
Healthcare|Biotechnology|US
$1.02
-0.02 (-1.92%)
Tangible Book / Share
$21.25
Cash / Share
$2.12
Next Earnings Report
Nov 12, 2026
EPS est. -$1.35 · Revenue est. $118.7K
Financing Filings (last 12 months)
12
Shelf registrations / offering prospectuses — latest Oct 2, 2026 (S-1). Possible dilution.

Upcoming Data Readouts (1)

Jul 2027
Est. completion
P1Alopecia Areata(AA)
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
NCT07049328n=30

Recent Press Releases

HCW Biologics' Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
Nov 6, 2026 · GlobeNewsWire
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company's Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer's 41st Annual Meeting
Nov 6, 2026 · GlobeNewsWire
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
Nov 5, 2026 · GlobeNewsWire
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
Oct 9, 2026 · GlobeNewsWire
HCW Biologics Announces Pricing of $1.5 Million Private Placement
Sep 24, 2026 · GlobeNewsWire
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
Sep 8, 2026 · GlobeNewsWire
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
Sep 2, 2026 · GlobeNewsWire
HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
Aug 25, 2026 · GlobeNewsWire
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
Aug 14, 2026 · GlobeNewsWire

SEC Filings (128)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 20268-KMaterial eventDocumentIndex
Oct 9, 2026EFFECTDocumentIndex
Oct 8, 2026DDocumentIndex
Oct 2, 2026S-1IPO / offering registrationDocumentIndex
Oct 1, 2026DEF 14AProxy / shareholder voteDocumentIndex
Sep 24, 20268-KMaterial eventDocumentIndex
Sep 10, 20268-KMaterial eventDocumentIndex
Sep 9, 2026PRER14ADocumentIndex
Sep 8, 20268-KMaterial eventDocumentIndex
Sep 8, 2026PRE 14AProxy / shareholder voteDocumentIndex
Aug 31, 2026EFFECTDocumentIndex
Aug 28, 2026S-1/AIPO / offering registrationDocumentIndex
Aug 20, 2026S-1IPO / offering registrationDocumentIndex
Aug 14, 202610-QQuarterly reportDocumentIndex
Aug 14, 20268-KMaterial eventDocumentIndex
Aug 14, 202610-Q/AQuarterly reportDocumentIndex
Aug 14, 20268-KMaterial eventDocumentIndex
Aug 6, 2026DDocumentIndex
Jul 29, 20268-KMaterial eventDocumentIndex
Jul 16, 2026POS AMDocumentIndex
Jul 1, 20268-KMaterial eventDocumentIndex
Jun 30, 20268-KMaterial eventDocumentIndex
Jun 26, 20268-KMaterial eventDocumentIndex
Jun 18, 2026EFFECTDocumentIndex
Jun 18, 2026S-1/AIPO / offering registrationDocumentIndex
Jun 16, 20268-KMaterial eventDocumentIndex
Jun 15, 20268-KMaterial eventDocumentIndex
Jun 8, 2026DDocumentIndex
Jun 8, 2026S-1IPO / offering registrationDocumentIndex
Jun 1, 20268-KMaterial eventDocumentIndex
May 27, 20268-KMaterial eventDocumentIndex
May 21, 20268-KMaterial eventDocumentIndex
May 18, 2026POS AMDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 13, 2026POS AMDocumentIndex
Apr 30, 20268-KMaterial eventDocumentIndex
Apr 30, 20268-KMaterial eventDocumentIndex
Apr 29, 2026EFFECTDocumentIndex